VivoSeq
Other

Satisfaction

0

Pipeline Programs↗

4

Active Trials↗

13

Companies Involved↗

Satisfaction is an early-stage landscape with 0 programs across 13 companies. The most active players are Bayer, AbbVie, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalUnited Therapeutics logo

United Therapeutics

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

54

clinical trials

Completed43 · 80%
Recruiting4 · 7%
Terminated4 · 7%
Unknown status3 · 6%

Clinical Trials

Trial Activity

54 trials

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Recruiting·MMayo Clinic·Phase 2·NCT07285044·27 enrolled
The Real-world Treatment Satisfaction by Gefapixiant in RCC
Recruiting·NNagoya City University·N/A·NCT06542484·63 enrolled
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT07101094·300 enrolled
Inflatable Penile Prostheses : Predicting Factors of Pump Misuse and Unsatisfaction
Recruiting·CCentre Hospitalier Universitaire de Nice·N/A·NCT04390230·120 enrolled
Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment
Completed·AbbVie logoAbbVie·Phase 4·NCT04609020·64 enrolled
A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
Completed·Bayer logoBayer·N/A·NCT03126773·1,570 enrolled
Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction
Completed·DDeNova Research·Phase 1·NCT04439825·45 enrolled
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Completed·CCephalon·N/A·NCT01400854·600 enrolled
Non-interventional, Real Life Study on Satisfaction With LNG-IUS in Spanish Young Women (18-30 Years Old) With Different Parity Status and Menstrual Bleeding Pattern
Completed·Bayer logoBayer·N/A·NCT03493295·587 enrolled
An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 4·NCT00653016·405 enrolled
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
Completed·CCephalon·Phase 3·NCT00228540
LCS16 vs. COC User Satisfaction and Tolerability Study
Completed·Bayer logoBayer·Phase 3·NCT03074045·145 enrolled
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Completed·AbbVie logoAbbVie·Phase 4·NCT06218251·100 enrolled
Comparison of Two Analgesic Pretreatment Techniques Before Spinal Needle Insertion for Pain Reduction and Maternal Satisfaction Level Assessment in Women Undergoing LSCS.
Completed·—·N/A·NCT04050059·62 enrolled
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
Completed·SSobi, Inc.·Phase 4·NCT04638829·60 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)